NCT04147078 Personalized DC Vaccine for Postoperative Cancer
| NCT ID | NCT04147078 |
| Status | Recruiting |
| Phase | Phase 1 |
| Sponsor | Sichuan University |
| Condition | Gastric Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 80 participants |
| Start Date | 2019-06-01 |
| Primary Completion | 2025-12-31 |
Trial Parameters
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
Brief Summary
The study is aimed to the test efficacy and safety of neoantigen-primed dendritic cell (DC) cell vaccine therapy for postoperative locally advanced gastric cancer, hepatocellular carcinoma, lung cancer and colorectal cancer, and to explore the biomarkers related to efficacy and adverse event.
Eligibility Criteria
Inclusion Criteria: * Participants with a first diagnosis of gastric cancer, hepatocellular carcinoma, non-small cell lung cancer, colorectal cancer who have undergone a curative resection or ablation * Anticipated life time \> 3month * Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1 * Adequate organ functions Exclusion Criteria: * Any evidence of tumor metastasis or co-existing malignant disease * Tumor emergency * Abnormal coagulation condition * Contagious diseases, such as hepatitis B virus, hepatitis C virus, human immunodefficiency virus, tuberculosis infection * Concomitant tumors * Immunological co-morbidities
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.